Please assess the completion status of the following clinical trial:

Trial Title: Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of a lead-in study (NCT00891462)~Exclusion Criteria:~* Use or anticipated use of any medication prohibited in this study~* Evidence of abnormal clinical laboratory values, vital signs, or electrocardiographic (ECG) results or the presence of abnormities in physical examination findings~* The presence of anti-cholinergic effects (eg, dry mouth, urinary retention, narrow angle glaucoma)~* QTcB of \>500 msec on both the pre-dose and post-dose ECG~* Women who are pregnant, intend to become pregnant, or are breast-feeding~* A life expectancy of less than 1 year~* Noncompliance with IP dosing and/or attending clinic visits during the lead-in study~* Significant interruption of double-blind therapy during the transition from the lead-in study into the extension study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Aclidinium bromide dose, inhaled, for 52 weeks of treatment
- 2 (Type: EXPERIMENTAL): Aclidinium bromide dose, inhaled, for 52 weeks of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).